EUVIMED · CrossrefJournal
Investigational New Drugs
ISSN 0167-6997 · Springer Science and Business Media LLC
Latest articles
Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence
The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells
Parthenolide enhances imatinib activity in gastrointestinal stromal tumor models through stress-associated apoptosis
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study
Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer
Qishen Yiqi Dripping Pills ameliorate doxorubicin-induced cardiotoxicity: a study based on bioinformatics and experimental verification
Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials
First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors
Correction to: Prostate cancer cells’ growth is decreased by novel MYC inhibitors
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study
Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors
Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes
Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database
Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database
A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer
Retraction Note: The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells
Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
Preclinical evaluation and mechanistic analysis of antitumor effects of the novel anti-CD147 antibody DS-1471a in liver cancer models
Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330
A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors
Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes
Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours
Prostate cancer cells’ growth is decreased by novel MYC inhibitors
Class-level DILI saturation and hERG-driven risk stratification among 2024–2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors
Network pharmacology-based therapeutic intervention of Mentha arvensis targeting cancer and doxorubicin-induced cardiotoxicity
Transforming cisplatin therapy: a localized, injectable poly(anhydride-ester) depot for safer and more effective head and neck cancer treatment
Recent progress of dendritic cell-derived exosomes in tumor immunotherapy
Volumes
2026 · 422025 · 1012024 · 842023 · 962022 · 1572021 · 1882020 · 1942019 · 1442018 · 1322017 · 992016 · 902015 · 1452014 · 1482013 · 1902012 · 2862011 · 1792010 · 1152009 · 762008 · 682007 · 752006 · 662005 · 722004 · 512003 · 462002 · 602001 · 452000 · 381999 · 421998 · 531997 · 421996 · 521995 · 581994 · 571993 · 521992 · 651991 · 731990 · 941989 · 511988 · 561987 · 55
EUVIMED